Cost-effectiveness analysis of tofacitinib compared with biologics in biologic-naïve patients with moderate-to-severe ulcerative colitis in Japan
T Kobayashi, M Hoshi, A Yuasa, S Arai, M Ikeda… - …, 2023 - Springer
Objective Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of ulcerative
colitis (UC). The objective of this study was to evaluate the long-term cost-effectiveness of …
colitis (UC). The objective of this study was to evaluate the long-term cost-effectiveness of …
Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative …
A Sardesai, A Dignass, P Quon, S Milev… - Journal of Medical …, 2021 - Taylor & Francis
Objectives Tofacitinib is an oral, small molecule Janus kinase (JAK) inhibitor for the
treatment of ulcerative colitis (UC). This study assessed the cost-effectiveness of tofacitinib …
treatment of ulcerative colitis (UC). This study assessed the cost-effectiveness of tofacitinib …
L'impact de la variation des mesures d'utilité sur le ratio coût-utilité incrémental des traitements indiqués pour la maladie de Crohn
MÈ Richard - 2020 - papyrus.bib.umontreal.ca
Objectifs: La maladie de Crohn (MC) et la colite ulcéreuse (CU) sont associées à un fardeau
socio-économique important. Au Canada, les analyses de coûts-utilité (ACU) sont …
socio-économique important. Au Canada, les analyses de coûts-utilité (ACU) sont …